Pioneering Microbiome Company Demonstrates Significant Clinical Results from Use of Microbiome-Based Synbiotic in Patients with Type 2 Diabetes SAN FRANCISCO, July 20, 2020 /PRNewswire/ -- Pendulum Therapeutics, an evidence-based microbiome company, announced today the publication of their clinical study in the journal BMJ Open Diabetes Research & Care showing the effectiveness of Pendulum's novel medical probiotic, Pendulum Glucose Control.